Towards elimination of measles and rubella in Italy: Progress and challenges.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 27 09 2019
accepted: 27 11 2019
entrez: 17 12 2019
pubmed: 17 12 2019
medline: 17 4 2020
Statut: epublish

Résumé

In the WHO European Region, endemic transmission of measles and rubella had been interrupted by 37 and 42 of the 53 member states (MSs), respectively, by 2018. Sixteen MSs are still endemic for measles, 11 for rubella and nine for both diseases, the latter including Italy. Elimination is documented by each country's National Verification Committee (NVC) through an annual status update (ASU). By analysing data used to produce the ASUs, we aimed to describe the advances made by Italy towards elimination of measles and rubella. Moreover, we propose a set of major interventions that could facilitate the elimination process. A total of 28 indicators were identified within the six core sections of the ASU form and these were evaluated for the period 2013-2018. These indicators relate to the incidence of measles/rubella; epidemiological investigation of cases; investigation of outbreaks; performance of the surveillance system; population immunity levels; and implementation of supplemental immunization activities (SIAs). From 2013 to 2018, epidemiological and laboratory analyses of measles cases in Italy improved substantially, allowing timely investigation in 2017 and 2018 of most outbreak and sporadic cases and identification of the majority of genotypic variants. Moreover, since 2017, vaccination coverage has increased significantly. Despite these improvements, several areas of concern emerged, prompting the following recommendations: i) improve outbreak monitoring; ii) strengthen the MoRoNet network; iii) increase the number of SIAs; iv) reinforce vaccination services; v) maintain regional monitoring; vi) design effective communication strategies; vii) foster the role of general practitioners and family paediatricians. The review of national ASUs is a crucial step to provide the NVC with useful insights into the elimination process and to guide the development of targeted interventions. Against this background, the seven recommendations proposed by the NVC have been shared with the Italian Ministry of Health and the Technical Advisory Group on measles and rubella elimination and have been incorporated into the new Italian Elimination Plan 2019-2023 as a technical aid to facilitate the achievement of disease elimination goals.

Identifiants

pubmed: 31841530
doi: 10.1371/journal.pone.0226513
pii: PONE-D-19-27165
pmc: PMC6913993
doi:

Substances chimiques

Measles Vaccine 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0226513

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Health Policy. 2015 Jun;119(6):760-9
pubmed: 25887486
Int J Equity Health. 2016 Feb 19;15:28
pubmed: 26892002
PLoS One. 2018 Oct 24;13(10):e0205147
pubmed: 30356247
Eur J Public Health. 2015 Dec;25(6):1117-9
pubmed: 25958239
Vaccine. 2014 Aug 27;32(38):4860-5
pubmed: 24262311
Med Mal Infect. 2016 May;46(3):117-22
pubmed: 26987960
Public Health. 2016 Jan;130:51-8
pubmed: 26427315
Euro Surveill. 2018 Apr;23(17):
pubmed: 29717694
Ig Sanita Pubbl. 2017 Sep-Oct;73(5):429-442
pubmed: 29433130
Euro Surveill. 2017 Sep 14;22(37):null
pubmed: 28933342
Euro Surveill. 2013 May 16;18(20):null
pubmed: 23725868
Soc Sci Med. 2014 Jul;112:1-11
pubmed: 24788111
Vaccine. 2018 May 31;36(23):3368-3374
pubmed: 29729995
MMWR Morb Mortal Wkly Rep. 2017 Nov 17;66(45):1256-1260
pubmed: 29145358
Vaccine. 2018 Feb 1;36(6):779-787
pubmed: 29325822
Hum Vaccin Immunother. 2018 Jul 3;14(7):1558-1565
pubmed: 29641945
Emerg Infect Dis. 2015 Aug;21(8):1444-6
pubmed: 26196266
Vaccine. 2012 May 28;30(25):3778-89
pubmed: 22172504
Vaccine. 2019 Mar 28;37(14):1954-1963
pubmed: 30827733
Ann Ig. 2012 Sep-Oct;24(5):397-405
pubmed: 23193896
Vaccine. 2019 Feb 8;37(7):984-990
pubmed: 30655175
Ann Ig. 2017 Jan-Feb;29(1):1-26
pubmed: 28067934
Vaccine. 2017 Aug 16;35(35 Pt B):4494-4498
pubmed: 28736200
Ital J Pediatr. 2018 Jun 14;44(1):67
pubmed: 29898770
Int J Infect Dis. 2019 Feb;79:199-201
pubmed: 30445191

Auteurs

Giovanna Adamo (G)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Valentina Baccolini (V)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Azzurra Massimi (A)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Domenico Barbato (D)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Rosario Cocchiara (R)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Carolina Di Paolo (C)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Annamaria Mele (A)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Sara Cianfanelli (S)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Aurora Angelozzi (A)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Fulvio Castellani (F)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Carla Salerno (C)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Claudia Isonne (C)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Antonino Bella (A)

Department of Infectious Diseases, National Institute of Health, Rome, Italy.

Antonietta Filia (A)

Department of Infectious Diseases, National Institute of Health, Rome, Italy.

Martina Del Manso (M)

Department of Infectious Diseases, National Institute of Health, Rome, Italy.

Melissa Baggieri (M)

National Reference Laboratory for Measles and Rubella, National Institute of Health, Rome, Italy.

Loredana Nicoletti (L)

National Reference Laboratory for Measles and Rubella, National Institute of Health, Rome, Italy.

Fabio Magurano (F)

National Reference Laboratory for Measles and Rubella, National Institute of Health, Rome, Italy.

Stefania Iannazzo (S)

Infectious Diseases and International Prophylaxis Office, Ministry of Health, Rome, Italy.

Carolina Marzuillo (C)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Paolo Villari (P)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH